...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta oncologica. >Comorbidity as a predictor of overall survival in prostate cancer patients treated with external beam radiotherapy combined with HDR brachytherapy boosts
【24h】

Comorbidity as a predictor of overall survival in prostate cancer patients treated with external beam radiotherapy combined with HDR brachytherapy boosts

机译：具有外梁放射治疗的前列腺癌患者的总生存率的共聚率，结合HDR Brachytherapy Boosts

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The risk stratification currently applied prior to curative treatment for localized prostate cancer (PC) does not take into account comorbidity or age. Therefore, we investigated the impact of comorbidity on overall survival (OS) in PC patients treated with external beam radiotherapy (EBRT) and high-dose rate (HDR) brachytherapy boost. Material and methods: At a single center, 611 consecutive patients diagnosed with localized PC from 1998 to 2004 underwent definitive EBRT (50 Gy) and HDR brachytherapy boosts (2 x 10Gy) combined with neoadjuvant total androgen blockade. Comorbidity was assessed with the Charlson comorbidity score. The impact of risk factors on OS and disease-free survival (DFS) was calculated using Cox proportional hazard ratios. Risk groups were defined as follows: low-risk PC: PSA<10, WHO grade 1 and T stage 1; high-risk PC: PSA>20 and/or WHO grade 3 and/or T stage 3a; intermediate-risk PC representing patients who did not fit either the low- or high-risk PC group.
机译：背景：目前施用的风险分层在局部前列腺癌（PC）治疗之前施用，不考虑合并症或年龄。因此，我们研究了合并症的影响在用外梁放射治疗（EBRT）和高剂量率（HDR）近距离放射治疗的PC患者中的整体存活（OS）的影响。材料和方法：在一个中心，连续611名诊断为1998至2004年诊断的局部PC，接受了明确的EBRT（50Gy）和HDR近距离放射治疗促进（2 x 10Gy）与Neoadjuvant全雄激素封闭。用Charlson合并症评分评估合并症。使用COX比例危险比计算危险因素对OS和无病生存（DFS）的影响。风险群体定义如下：低风险PC：PSA <10，世卫组级1和T阶段1;高风险PC：PSA> 20和/或WHO 3和/或T阶段3A;代表不适合低风险或高风险PC组的患者的中间风险PC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号